1-[2-(1H-indol-3-yl)ethyl]-4-acetyl-3-hydroxy-5-(4-isopropylphenyl)-1H-pyrrole-2(5H)-one | 697238-36-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 英文名称: 1-[2-(1H-indol-3-yl)ethyl]-4-acetyl-3-hydroxy-5-(4-isopropylphenyl)-1H-pyrrole-2(5H)-one
• 英文别名: 4-acetyl-3-hydroxy-1-[2-(1H-indol-3-yl)ethyl]-5-[4-(propan-2-yl)phenyl]-1,5-dihydro-2H-pyrrol-2-one；3-acetyl-4-hydroxy-1-[2-(1H-indol-3-yl)ethyl]-2-(4-propan-2-ylphenyl)-2H-pyrrol-5-one
• CAS: 697238-36-1
• 化学式: C₂₅H₂₆N₂O₃
• 分子量: 402.493
• InChiKey: ATZIGTFGSHRCPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  73.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  色胺 、 乙酰丙酮酸甲酯 、 4-异丙基苯甲醛 以 1,4-二氧六环 为溶剂， 反应 24.0h， 以85%的产率得到1-[2-(1H-indol-3-yl)ethyl]-4-acetyl-3-hydroxy-5-(4-isopropylphenyl)-1H-pyrrole-2(5H)-one
  参考文献：
  名称：

  Synthesis of 1-[2-(1H-Indol-3-yl)ethyl]-4-acetyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones

  摘要：

  1-[2-(1H-indol-3-yl)ethyl]-4-acetyl-3-hydroxy-5-phenyl-1H-pyrrole-2(5H)-ones were synthesized by the short heating of a mixture of tryptamine, aromatic aldehyde, and methyl acetylpyruvate followed by stirring at room temperature for one day.

  DOI：

  10.1134/s1070363218060373

文献信息

• A Combination Strategy to Inhibit Pim-1: Synergism between Noncompetitive and ATP-Competitive Inhibitors
  作者：Mattia Mori、Cristina Tintori、Robert Selwyne Arul Christopher、Marco Radi、Silvia Schenone、Francesca Musumeci、Chiara Brullo、Patrizia Sanità、Simona Delle Monache、Adriano Angelucci、Miroslava Kissova、Emmanuele Crespan、Giovanni Maga、Maurizio Botta

  DOI：10.1002/cmdc.201200480

  日期：2013.3

  a synergistic inhibitory effect in enzymatic assays when tested in combination with ATP‐competitive inhibitors. A synergistic effect in the inhibition of cell proliferation by ATP‐competitive and ATP‐noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all Pim‐1 inhibitors tested in showed synergism with the known anticancer agent, paclitaxel. These results further

  Pim-1是一种丝氨酸/苏氨酸激酶，主要参与各种癌症（尤其是白血病，淋巴瘤和实体瘤，例如前列腺癌，胰腺癌和结肠癌）的发生和发展，被认为是针对这些恶性肿瘤的潜在药物靶标。为了发现新的有效Pim-1抑制剂，对先前确定的具有ATP竞争性的吲哚基-吡咯烷酮骨架进行了扩展，以推导结构-活性关系数据。还进行了虚拟筛选，从而发现了其他与ATP竞争的抑制剂以及一系列2-氨基噻唑衍生物，这些衍生物对ATP和肽底物均无竞争性。这种作用机制类似于变构抑制作用，以前尚未针对Pim-1进行过表征。尤其，对2-氨基噻唑类化合物的进一步评估表明，与ATP竞争性抑制剂联合测试时，在酶法测定中具有协同抑制作用。在前列腺癌细胞系（PC3）中也观察到了由ATP竞争性和ATP非竞争性化合物抑制细胞增殖的协同作用，其中所有测试的Pim-1抑制剂均与已知的抗癌药紫杉醇具有协同作用。这些结果进一步将Pim-1确立为癌症治疗的目标，并突
• NMDA RECEPTOR MODULATORS AND USES RELATED THERETO
  申请人：EMORY UNIVERSITY

  公开号：US20150196540A1

  公开（公告）日：2015-07-16

  This disclosure relates to NMDA modulators and used related thereto such as for treatment of central nervous system disorders. In certain embodiments, compounds disclosed herein are NR2C subunit-selective NMDA potentiators. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiments, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof. In certain embodiments, the disclosure relates to methods of treating or preventing nervous system disorders comprising administering an effective amount of a composition comprising compound disclosed herein to a subject in need thereof.

  本公开涉及NMDA调节剂及其相关用途，例如用于治疗中枢神经系统疾病。在某些实施例中，本文所披露的化合物是NR2C亚单位选择性NMDA增强剂。在某些实施例中，本公开考虑化合物和制药组合物。在某些实施例中，本公开考虑化合物作为前药，可选择地用一个或多个取代基，衍生物或其盐替代。在某些实施例中，本公开涉及治疗或预防神经系统疾病的方法，包括向需要治疗的受试者施用含有本文所披露的化合物的有效量的组合物。
• US9737522B2
  申请人：——

  公开号：US9737522B2

  公开（公告）日：2017-08-22
• Synthesis of 1-[2-(1H-Indol-3-yl)ethyl]-4-acetyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones
  作者：O. E. Nasakin、M. I. Kazantseva、L. I. Varkentin、V. L. Gein

  DOI：10.1134/s1070363218060373

  日期：2018.6

  1-[2-(1H-indol-3-yl)ethyl]-4-acetyl-3-hydroxy-5-phenyl-1H-pyrrole-2(5H)-ones were synthesized by the short heating of a mixture of tryptamine, aromatic aldehyde, and methyl acetylpyruvate followed by stirring at room temperature for one day.